These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 3102144)

  • 1. A kinetic analysis of fibrinogenolysis during plasminogen activator therapy.
    Noe DA; Bell WR
    Clin Pharmacol Ther; 1987 Mar; 41(3):297-303. PubMed ID: 3102144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
    Bovill EG; Terrin ML; Stump DC; Berke AD; Frederick M; Collen D; Feit F; Gore JM; Hillis LD; Lambrew CT
    Ann Intern Med; 1991 Aug; 115(4):256-65. PubMed ID: 1906692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator.
    Mueller HS; Rao AK; Forman SA
    J Am Coll Cardiol; 1987 Sep; 10(3):479-90. PubMed ID: 3114349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
    Weitz JI; Leslie B; Ginsberg J
    J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of tissue-type plasminogen activator characterized by computer-assisted simulation.
    Tiefenbrunn AJ; Graor RA; Robison AK; Lucas FV; Hotchkiss A; Sobel BE
    Circulation; 1986 Jun; 73(6):1291-9. PubMed ID: 3084127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
    Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
    Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis.
    Weitz JI; Leslie B; Hirsh J; Klement P
    J Clin Invest; 1993 Apr; 91(4):1343-50. PubMed ID: 7682569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of human recombinant tissue-type plasminogen activator on clinical and laboratory parameters of hemostasis and systemic plasminogen activation in the dog and the rat.
    Bloom JC; Sellers TS; Gries GC; Wheeldon EB; O'Brien SR; Lewis HB
    Thromb Haemost; 1988 Oct; 60(2):271-9. PubMed ID: 3146143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group.
    Stump DC; Califf RM; Topol EJ; Sigmon K; Thornton D; Masek R; Anderson L; Collen D
    Circulation; 1989 Nov; 80(5):1222-30. PubMed ID: 2509104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)].
    Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
    Klin Wochenschr; 1988; 66 Suppl 12():102-8. PubMed ID: 3126339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue plasminogen activator: a new thrombolytic agent.
    Crabbe SJ; Cloninger CC
    Clin Pharm; 1987 May; 6(5):373-86. PubMed ID: 3117481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized dose-ranging study of rt-PA in acute myocardial infarction. Effects on coronary patency and fibrinolytic parameters.
    Koster RW; van Stralen R; McNeill AJ; Adgey AA; Fox KA; Dymond D; Sponzilli C; Jewitt D; Bucknall C; Kluft C
    Eur Heart J; 1990 Aug; 11(8):730-9. PubMed ID: 2118853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of tissue-type plasminogen activator produced by recombinant DNA technology.
    Sobel BE
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):40B-44B. PubMed ID: 3117860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double blind placebo controlled study of early and late administration of recombinant tissue plasminogen activator in acute myocardial infarction.
    McNeill AJ; Cunningham SR; Flannery DJ; Dalzell GW; Wilson CM; Campbell NP; Khan MM; Patterson GC; Webb SW; Adgey AA
    Br Heart J; 1989 Apr; 61(4):316-21. PubMed ID: 2496740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
    Gurbel PA; Anderson RD; MacCord CS; Scott H; Serebruany V; Herzog WR
    Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial.
    Collen D; Topol EJ; Tiefenbrunn AJ; Gold HK; Weisfeldt ML; Sobel BE; Leinbach RC; Brinker JA; Ludbrook PA; Yasuda I
    Circulation; 1984 Dec; 70(6):1012-7. PubMed ID: 6388898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers.
    Verstraete M; Su CA; Tanswell P; Feuerer W; Collen D
    Thromb Haemost; 1986 Aug; 56(1):1-5. PubMed ID: 3095944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.